[1]
|
Rudin, C.M., Brambilla, E., Faivre-Finn, C. and Sage, J. (2021) Small-Cell Lung Cancer. Nature Reviews Disease Pri-mers, 7, Article No. 3. https://doi.org/10.1038/s41572-020-00235-0
|
[2]
|
Waqar, S.N. and Morgensztern, D. (2017) Treatment Advances in Small Cell Lung Cancer (SCLC). Pharmacology & Therapeutics, 180, 16-23. https://doi.org/10.1016/j.pharmthera.2017.06.002
|
[3]
|
Salem, A., Mistry, H., Hatton, M., Locke, I., Monnet, I., Blackhall, F. and Faivre-Finn, C. (2019) Association of Chemoradiotherapy with Outcomes Among Patients with Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology, 5, Arti-cle ID: e185335.
https://doi.org/10.1001/jamaoncol.2018.5335
|
[4]
|
Simone II, C.B., Bogart, J.A., Cabrera, A.R., Daly, M.E., De-Nunzio, N.J., Detterbeck, F., et al. (2020) Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 10, 158-173. https://doi.org/10.1016/j.prro.2020.02.009
|
[5]
|
Ganti, A.K.P., Loo, B.W., Bassetti, M., Blakely, C., Chiang, A., D’Amico, T.A., et al. (2021) Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 1441-1464. https://doi.org/10.6004/jnccn.2021.0058
|
[6]
|
Faivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., Le Pechoux, C., McMenemin, R., Moham-med, N., O’Brien, M., Pantarotto, J., Surmont, V., Van Meerbeeck, J., Woll, P.J., Lorigan, P., et al. (2017) Concurrent Once-Daily versus Twice-Daily Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer (CONVERT): An Lung Cancer (TA Leal and N Sethakorn, Section Editors) Open-Label, Phase 3, Randomised, Superi-ority Trial. The Lancet Oncology, 18, 1116-1125.
https://doi.org/10.1016/S1470-2045(17)30318-2
|
[7]
|
Steel, G.G. (1979) Terminology in the Description of Drugradiation Interactions. International Journal of Radiation Oncology, Biology, Physics, 5, 1145-1150. https://doi.org/10.1016/0360-3016(79)90634-5
|
[8]
|
Donlon, N.E., Power, R., Hayes, C., Reynolds, J.V. and Lysaght, J. (2021) Radiotherapy, Immunotherapy, and the Tumour Microenvironment: Turning an Immunosuppressive Milieu into a Therapeutic Opportunity. Cancer Letters, 502, 84-96. https://doi.org/10.1016/j.canlet.2020.12.045
|
[9]
|
Postow, M.A., Callahan, M.K., Barker, C.A., Yamada, Y., Yuan, J., Kitano, S., et al. (2012) Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. New England Journal of Medicine, 366, 925-931.
https://doi.org/10.1056/NEJMoa1112824
|
[10]
|
Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. (2015) Radiation and Dual Checkpoint Blockade Activate Non-Redundant Immune Mechanisms in Cancer. Nature, 520, 373-377.
https://doi.org/10.1038/nature14292
|
[11]
|
Hiniker, S.M., Reddy, S.A., Maecker, H.T., Subrahmanyam, P.B., Ros-enberg-Hasson, Y., Swetter, S.M., et al. (2016) A Prospective Clinical Trial Combining Radiation Therapy with System-ic Immunotherapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 96, 578-588.
https://doi.org/10.1016/j.ijrobp.2016.07.005
|
[12]
|
Murphy, B., Walker, J., Bassale, S., Monaco, D., Jaboin, J.J., Ciporen, J., et al. (2017) Concurrent Radiosurgery and Immunotherapy Is Associated with Improved Intracranial Tumor Control in Patients with Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics, 99, E523-E524.
https://doi.org/10.1016/j.ijrobp.2017.06.1857
|
[13]
|
Arnett, A.L.H., Kottschade, L., Wilhite, T.J., Youland, R.S., Hocum, C., Whitaker, T.J., et al. (2017) Toxicity of Concurrent and Sequential PD-1 Immune Check Point Inhibitors with Conventional and Hypofractionated Radiation Therapy in Patients with Metastatic Disease. International Journal of Radiation Oncology, Biology, Physics, 99, E749.
https://doi.org/10.1016/j.ijrobp.2017.06.2402
|
[14]
|
Jie, Y., Gu, A., Fu, P. and Kong, F.M.S. (2020) Does Radiation Increase the Risk of Immunotherapy Related Pneumonitis in Cancer Patients with Thorax Radiotherapy Combined Im-mune Checkpoint Inhibitors: A Meta-Analysis. Journal of Clinical Oncology, 38, e15099. https://doi.org/10.1200/JCO.2020.38.15_suppl.e15099
|
[15]
|
Peters, S., Pujol, J.L., Dafni, U., Dómine, M., Popat, S., Reck, M., et al. (2022) Consolidation Nivolumab and Ipilimumab Versus Observation in Limited-Disease Small-Cell Lung Cancer after Chemo-Radiotherapy—Results from the Randomised Phase II ETOP/IFCT 4-12 STIMULI Trial. An-nals of Oncology, 33, 67-79.
https://doi.org/10.1016/j.annonc.2021.09.011
|
[16]
|
Welsh, J.W., Heymach, J.V., Guo, C., Menon, H., Klein, K., Cushman, T.R., et al. (2020) Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Lim-ited-Stage SCLC. Journal of Thoracic Oncology, 15, 1919-1927. https://doi.org/10.1016/j.jtho.2020.08.022
|
[17]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M, Shentu, Y., Rangwala, R., Brahmer, J.R. and KEYNOTE-024 Investigators (2016) Pembrolizumab versus Chem-otherapy for PD-L1-Positive Non-Small-Cell Lung Cancer Clinical Trial. New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774
|
[18]
|
U.S. National Library of Medicine (2018) Atezolizumab after Concurrent Chemo-Radiotherapy versus Chemo-Radiotherapy alone in Limited Disease Small-Cell Lung Can-cer.
|
[19]
|
U.S. National Library of Medicine (2018) Study of Durvalumab Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy.
|
[20]
|
Senan, S., Okamoto, I., Lee, G.W., Chen, Y., Niho, S., Mak, G., Yao, W., Shire, N., Jiang, H. and Cho, B.C. (2020) Design and Rationale for a Phase III, Randomized, Placebo-Controlled Trial of Durvalumab with or without Tremelimumab after Concurrent Chemoradiotherapy for Patients with Limited-Stage Small-Cell Lung Cancer: The ADRIATIC Study. Clinical Lung Cancer, 21, E84-E88. https://doi.org/10.1016/j.cllc.2019.12.006
|
[21]
|
U.S. Na-tional Library of Medicine (2018) Chemoradiation with Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer.
|
[22]
|
U.S. National Library of Medicine (2019) Testing the Addition of a New Immu-notherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC).
|
[23]
|
Ross, H.J., Hu, C., Higgins, K.A., Jabbour, S.K., Kozono, D.E., Owonikoko, T.K., et al. (2020) NRG Oncology/Alliance LU005: A Phase II/III Randomized Clinical Trial of Chemora-diation versus Chemoradiation plus Atezolizumab in Limited Stage Small Cell Lung Cancer. Journal of Clinical Oncology, 38, TPS9082.
|
[24]
|
Tachihara, M., Tsujino, K., Ishihara, T., Hayashi, H., Sato, Y., Kurata, T., Sugawara, S., Okamoto, I., Teraoka, S., Azuma, K., Daga, H., Yamaguchi, M., Kodaira, T., Satouchi, M., Shimokawa, M., Yamamoto, N., Nak-agawa, K. and Members of the West Japan Oncology Group (WJOG) (2021) Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research, 13, 9167-9173. https://doi.org/10.2147/cmar.s336262
|
[25]
|
U.S. National Library of Medicine (2020) Efficacy and Safety of Standard of Care plus Durvalumab in Patients with Limited Disease Small Cell Lung Cancer (DOLPHIN).
|
[26]
|
Efficacy and Safety of SHR-1316 in Combination with Chemo-Radiotherapy in Patients with LS-SCLC.
https://clinicaltrials.gov/ct2/show/NCT04691063
|
[27]
|
U.S. National Library of Medicine (2021) Durvalumab with Chemotherapy Followed By Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer.
|
[28]
|
Jagodinsky, J.C., Harari, P.M. and Morris, Z.S. (2020) The Promise of Combining Radiation Therapy with Immunotherapy. Interna-tional Journal of Radiation Oncology, Biology, Physics, 108, 6-16.
https://doi.org/10.1016/j.ijrobp.2020.04.023
|
[29]
|
Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.D., Mauceri, H., Beckett, M., Darga, T., Huang, X., Gajewski, T.F., Chen, Z.J., Fu, Y.X. and Weichselbaum, R.R. (2014) STINGdependent Cytosolic DNA Sensing Promotes Radiationinduced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity, 41, 843-852. https://doi.org/10.1016/j.immuni.2014.10.019
|
[30]
|
Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., Camphausen, K., Luiten, R.M., De Ru, A.H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F.A., Spits, H., Schlom, J., Van Veelen, P. and Neefjes, J.J. (2006) Radiation Modulates the Peptide Repertoire, Enhances MHC Class I Expression, and Induces Successful Antitumor Immunotherapy. Journal of Experimental Medi-cine, 203, 1259-1271.
https://doi.org/10.1084/jem.20052494
|